Claims for Patent: 10,842,780

Summary for Patent: 10,842,780

Title:	Pharmaceutical composition for modified release
Abstract:	A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPas or more at a 5% aqueous solution at 25.degree. C. is disclosed.
Inventor(s):	Takaishi; Yuuki (Tokyo, JP), Takahashi; Yutaka (Tokyo, JP), Nishizato; Takashi (Tokyo, JP), Murayama; Daisuke (Tokyo, JP), Murayama; Emiko (Tokyo, JP), Nakamura; Soichiro (Tokyo, JP), Sako; Kazuhiro (Tokyo, JP)
Assignee:	ASTELLAS PHARMA INC. (Tokyo, JP)
Application Number:	15/432,854
Patent Claims:	1. A pharmaceutical composition, comprising 10 mg to 200 mg of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide, or a pharmaceutically acceptable salt thereof, in a sustained release hydrogel-forming formulation comprising a hydrogel-forming polymer having an average molecular weight of 100,000 to 8,000,000 and an additive having a water solubility of at least 0.1 g/mL at 20.+-.5.degree. C., wherein the hydrogel-forming polymer is at least one compound selected from the group consisting of polyethylene oxide, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose sodium, hydroxyethyl cellulose, and a carboxyvinyl polymer, wherein the additive is at least one selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone, D-mannitol, D-sorbitol, xylitol, lactose, sucrose, anhydrous maltose, D-fructose, dextran, glucose, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, polyoxyethylene sorbitan higher fatty acid ester, sodium chloride, magnesium chloride, citric acid, tartaric acid, glycine, (3-alanine, lysine hydrochloride, and meglumine, and wherein a drug dissolution rate from the pharmaceutical composition is 39% or less after 1.5 hours, and at least 75% after 7 hours, as measured in accordance with United States Pharmacopoeia in 900 mL of a USP buffer having a pH of 6.8 at a paddle rotation speed of 200 rpm. 2. The pharmaceutical composition according to claim 1, wherein the additive is at least one selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone, D-mannitol, lactose, sucrose, sodium chloride, and polyoxyethylene polyoxypropylene glycol. 3. The pharmaceutical composition according to claim 1, wherein an amount of the additive is 5% by weight to 75% by weight with respect to a total weight of the pharmaceutical composition. 4. The pharmaceutical composition according to claim 3, wherein the amount of the additive is 5% by weight to 70% by weight with respect to the total weight of the pharmaceutical composition. 5. The pharmaceutical composition according to claim claim 1, wherein the hydrogel-forming polymer is at least one compound selected from the group consisting of polyethylene oxide, hydoxypropyl methylcellulose, and hydroxypropyl cellulose. 6. The pharmaceutical composition according to claim 1, further comprising an antioxidant. 7. The pharmaceutical composition according to claim 6, wherein the antioxidant is at least one compound selected from the group consisting of butyl hydroxytoluene, propyl gallate, and sodium ascorbate. 8. The pharmaceutical composition according to claim 7, wherein the antioxidant is butyl hydroxytoluene. 9. The pharmaceutical composition according to claim 6, wherein an amount of the antioxidant is 0.025% by weight to 0.25% by weight with respect to a total weight of the pharmaceutical composition. 10. The pharmaceutical composition according to claim 1, further comprising a stabilizer. 11. The pharmaceutical composition according to claim 10, wherein the stabilizer is at least one compound selected from the group consisting of yellow ferric oxide, red ferric oxide, and black iron oxide. 12. The pharmaceutical composition according to claim 11, wherein the stabilizer is yellow ferric oxide and/or red ferric oxide. 13. The pharmaceutical composition according to claim 10, wherein an amount of the stabilizer is 0.05% by weight to 1% by weight with respect to a total weight of the pharmaceutical composition. 14. The pharmaceutical composition according to claim 1, wherein the drug dissolution rate from the pharmaceutical composition is at least 92% after 4.5 hours. 15. The pharmaceutical composition according to claim 1, wherein the average molecular weight of the hydrogel-forming polymer is 100,000 to 2,000,000. 16. The pharmaceutical composition according to claim 1, comprising 10 mg to 200 mg of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide. 17. A tablet, comprising the pharmaceutical composition according to claim 1. 18. A tablet, comprising the pharmaceutical composition according to claim 16. 19. A method for treating overactive bladder comprising administering the tablet according to claim 17 to a subject in need thereof. 20. A method for treating overactive bladder comprising administering the tablet according to claim 18 to a subject in need thereof. 21. The pharmaceutical composition according to claim 1, wherein the average molecular weight of the hydrogel-forming polymer is 100,000 to 5,000,000. 22. A pharmaceutical composition, comprising 10 mg to 200 mg of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide, or a pharmaceutically acceptable salt thereof, in a sustained release hydrogel-forming formulation comprising a means for forming a hydrogel and a means for ensuring penetration of water into the pharmaceutical composition, wherein a drug dissolution rate from the pharmaceutical composition is 39% or less after 1.5 hours, and at least 75% after 7 hours, as measured in accordance with United States Pharmacopoeia in 900 mL of a USP buffer having a pH of 6.8 at a paddle rotation speed of 200 rpm. 23. The pharmaceutical composition according to claim 22, comprising 10 mg to 200 mg of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide. 24. A tablet, comprising the pharmaceutical composition according to claim 22. 25. A tablet, comprising the pharmaceutical composition according to claim 23.